Guilin Sanjin Pharmaceutical Co., Ltd. (SHE:002275)

Market Cap	8.02B
Revenue (ttm)	2.19B
Net Income (ttm)	521.53M
Shares Out	587.57M
EPS (ttm)	0.89
PE Ratio	19.74
Forward PE	15.87
Dividend	0.60 (4.40%)
Ex-Dividend Date	Nov 26, 2024

Volume	2,426,700
Average Volume	2,541,539
Open	13.84
Previous Close	13.71
Day's Range	13.64 - 13.86
52-Week Range	12.07 - 16.99
Beta	0.47
RSI	46.04
Earnings Date	Apr 26, 2025

About SHE:002275

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand; and Naomaitai capsules, etc. It also produces TCM preparations. Guilin Sanjin Pharmaceutical Co., Ltd. was founded in 1967 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1967
• Employees: 2,615
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002275

Financial Performance

In 2024, SHE:002275's revenue was 2.19 billion, an increase of 1.03% compared to the previous year's 2.17 billion. Earnings were 521.53 million, an increase of 23.79%.